Abstract
Clinicians and researchers are exploring safer and novel treatment strategies for treating the ever-prevalent Parkinson’s disease (PD) across the globe. Several therapeutic strategies are used clinically for PD, including dopamine replacement therapy, DA agonists, MAO-B blockers, COMT blockers, and anticholinergics. Surgical interventions such as pallidotomy, particularly deep brain stimulation (DBS), are also employed. However, they only provide temporal and symptomatic relief. Cyclic adenosine monophosphate (cAMP) is one of the secondary messengers involved in dopaminergic neurotransmission. Phosphodiesterase (PDE) regulates cAMP and cGMP intracellular levels. PDE enzymes are subdivided into families and subtypes which are expressed throughout the human body. PDE4 isoenzyme- PDE4B subtype is overexpressed in the substantia nigra of the brain. Various studies have implicated multiple cAMP-mediated signaling cascades in PD, and PDE4 is a common link that can emerge as a neuroprotective and/or disease-modifying target. Furthermore, a mechanistic understanding of the PDE4 subtypes has provided perceptivity into the molecular mechanisms underlying the adverse effects of phosphodiesterase-4 inhibitors (PDE4Is). The repositioning and development of efficacious PDE4Is for PD have gained much attention. This review critically assesses the existing literature on PDE4 and its expression. Specifically, this review provides insights into the interrelated neurological cAMP-mediated signaling cascades involving PDE4s and the potential role of PDE4Is in PD. In addition, we discuss existing challenges and possible strategies for overcoming them.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Not applicable.
Code Availability
Not applicable.
References
Abdulrahim H, Thistleton S, Adebajo AO et al (2015) Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. https://doi.org/10.1517/14656566.2015.1034107
Ahn JH, Jee YS, McAvoy T et al (2007) The B″/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc Natl Acad Sci USA 104:9876–9881. https://doi.org/10.1073/pnas.0703589104
Aldrich A, Bosch ME, Fallet R et al (2016) Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3). Ann Neurol. https://doi.org/10.1002/ana.24815
Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ (2021) Advances in oral drug delivery. Front Pharmacol. https://doi.org/10.3389/fphar.2021.618411
Alvarez R, Sette C, Yang D, et al (1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol
Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic lewy body disease. J Biol Chem. https://doi.org/10.1074/jbc.M600933200
Atkins CM, Oliva AA, Alonso OF et al (2007) Modulation of the cAMP signaling pathway after traumatic brain injury. Exp Neurol. https://doi.org/10.1016/j.expneurol.2007.08.011
Baillie GS, MacKenzie SJ, McPhee I, Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol. https://doi.org/10.1038/sj.bjp.0703636
Banner KH, Trevethick MA (2004) PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 25:430–436. https://doi.org/10.1016/j.tips.2004.06.008
Barnette MS, Grous M, Cieslinski LB et al (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396–1402
Bateup HS, Svenningsson P, Kuroiwa M et al (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11:932–939. https://doi.org/10.1038/nn.2153
Beard MB, Olsen AE, Jones RE et al (2000) UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J Biol Chem. https://doi.org/10.1074/jbc.275.14.10349
Bennett EJ, Shaler TA, Woodman B et al (2007) Global changes to the ubiquitin system in Huntington’s disease. Nature. https://doi.org/10.1038/nature06022
Betarbet R, Canet-Aviles RM, Sherer TB et al (2006) Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2005.12.003
Bhat NR, Zhang P (1999) Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal- regulated kinase in hydrogen peroxide-induced cell death. J Neurochem. https://doi.org/10.1046/j.1471-4159.1999.0720112.x
Bhat A, Ray B, Mahalakshmi AM et al (2020) Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacol Res. https://doi.org/10.1016/j.phrs.2020.105078
Bibb JA, Snyder GL, Nishi A et al (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. https://doi.org/10.1038/45251
Bilge SS, Günaydin C, Önger ME et al (2020) Neuroprotective action of agmatine in rotenone-induced model of Parkinson’s disease: role of BDNF/cREB and ERK pathway. Behav Brain Res. https://doi.org/10.1016/j.bbr.2020.112692
Blokland A, Heckman P, Vanmierlo T et al (2019a) Phosphodiesterase type 4 inhibition in CNS diseases. Trends Pharmacol Sci 40:971–985. https://doi.org/10.1016/j.tips.2019.10.006
Blokland A, Van Duinen MA, Sambeth A et al (2019b) Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiol Aging 77:37–43. https://doi.org/10.1016/j.neurobiolaging.2019.01.014
Bohush A, Niewiadomska G, Filipek A (2018) Role of mitogen activated protein kinase signaling in Parkinson’s disease. Int J Mol Sci 19:2973. https://doi.org/10.3390/ijms19102973
Bolger GB (1994) Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal 6:851–859. https://doi.org/10.1016/0898-6568(94)90018-3
Bomsztyk K, Toivola B, Emery DW et al (1990) Role of cAMP in interleukin-1-induced κ light chain gene expression in murine B cell line. J Biol Chem 265:9413–9417. https://doi.org/10.1016/s0021-9258(19)38864-7
Boomkamp SD, McGrath MA, Houslay MD, Barnett SC (2014) Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model. Br J Pharmacol. https://doi.org/10.1111/bph.12588
Boyd A, Aragon IV, Rich J et al (2021) Assessment of pde4 inhibitor-induced hypothermia as a correlate of nausea in mice. Biology (basel). https://doi.org/10.3390/biology10121355
Brami-Cherrier K, Valjent E, Garcia M et al (2002) Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J Neurosci 22:8911–8921. https://doi.org/10.1523/jneurosci.22-20-08911.2002
Brecht S, Kirchhof R, Chromik A et al (2005) Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci. https://doi.org/10.1111/j.1460-9568.2005.03857.x
Brown AM, Deuten AY, Colbran RJ (2005) Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur J Neurosci. https://doi.org/10.1111/j.1460-9568.2005.04190.x
Burgin AB, Magnusson OT, Singh J et al (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. https://doi.org/10.1038/nbt.1598
Cai CZ, Zhou HF, Yuan NN et al (2019) Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. Phytomedicine. https://doi.org/10.1016/j.phymed.2019.152842
Cantó C, Jiang LQ, Deshmukh AS et al (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. https://doi.org/10.1016/j.cmet.2010.02.006
Cao S, Theodore S, Standaert DG (2010) Fcy receptors are required for NF-kB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson’s disease. Mol Neurodegener 5:42. https://doi.org/10.1186/1750-1326-5-42
Cao S, Standaert DG, Harms AS (2012) The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J Neuroinflammation. https://doi.org/10.1186/1742-2094-9-259
Casacchia M, Meco G, Castellana F et al (1983) Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson’s disease. Pharmacol Res Commun. https://doi.org/10.1016/S0031-6989(83)80017-4
Chalovich EM, Zhu JH, Caltagarone J et al (2006) Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem. https://doi.org/10.1074/jbc.M602632200
Chao AC, De Sauvage FJ, Dong YJ et al (1994) Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 13:1065–1072. https://doi.org/10.1002/j.1460-2075.1994.tb06355.x
Chen CN, Denome S, Davis RL (1986) Molecular analysis of cDNA clones and the corresponding genomic coding sequences of the Drosophila dunce+ gene, the structural gene for cAMP phosphodiesterase. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.83.24.9313
Chen J, Ren Y, Gui C et al (2018a) Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T α-synuclein model of Parkinson’s disease. Cell Death Dis. https://doi.org/10.1038/s41419-018-0722-7
Chen J, Yu H, Zhong J et al (2018b) The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion. Brain Res Bull 137:98–106. https://doi.org/10.1016/j.brainresbull.2017.11.010
Chen MY, Fan K, Zhao LJ et al (2021) Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson’s disease. Bioengineered 12:708–719. https://doi.org/10.1080/21655979.2021.1883279
Chen J, Zhu Q, Cai C et al (2022) α -mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha- synuclein in Parkinson ’ s disease models through PKA activation. Phytomedicine. https://doi.org/10.1016/j.phymed.2022.154125
Cheng X, Ji Z, Tsalkova T, Mei F (2008) Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (shanghai) 40:651–662. https://doi.org/10.1111/j.1745-7270.2008.00438.x
Cherry JA, Davis RL (1999) Cyclic amp phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 407:287–301. https://doi.org/10.1002/(SICI)1096-9861(19990503)407:2%3c287::AID-CNE9%3e3.0.CO;2-R
Choi WS, Eom DS, Han BS et al (2004) Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem. https://doi.org/10.1074/jbc.M311164200
Choi JS, Park C, Jeong JW (2010) AMP-activated protein kinase is activated in Parkinson’s disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun. https://doi.org/10.1016/j.bbrc.2009.11.022
Cholanians AB, Phan AV, Ditzel EJ et al (2016) Arsenic induces accumulation of α-synuclein: implications for synucleinopathies and neurodegeneration. Toxicol Sci. https://doi.org/10.1093/toxsci/kfw117
Chung JH (2012) Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte. https://doi.org/10.4161/adip.21158
Colicelli J, Birchmeier C, Michaeli T et al (1989) Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.86.10.3599
Conti M, Richter W, Mehats C et al (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493–5496. https://doi.org/10.1074/jbc.R200029200
Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of Sildenafil. J Biol Chem 274:13729–13732. https://doi.org/10.1074/jbc.274.20.13729
Crocker CE, Khan S, Cameron MD et al (2011) JNK inhibition protects dopamine neurons and provides behavioral improvement in a rat 6-hydroxydopamine model of Parkinson’s disease. ACS Chem Neurosci. https://doi.org/10.1021/cn1001107
Dagda RK, Gusdon AM, Pien I et al (2011) Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson’s disease. Cell Death Differ 18:1914–1923. https://doi.org/10.1038/cdd.2011.74
Dagda RK, Pien I, Wang R et al (2014) Beyond the mitochondrion: cytosolic PINK1 remodels dendrites through protein kinase A. J Neurochem. https://doi.org/10.1111/jnc.12494
De Rooij J, Zwartkruis FJT, Verheijen MHG et al (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. https://doi.org/10.1038/24884
Degerman E, In’tZandt R, Pålbrink A et al (2017) Inhibition of phosphodiesterase 3, 4, and 5 induces endolymphatic hydrops in mouse inner ear, as evaluated with repeated 9.4T MRI. Acta Otolaryngol 137:8–15. https://doi.org/10.1080/00016489.2016.1211320
Dehay B, Bové J, Rodríguez-Muela N et al (2010) Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci 30:12535–12544. https://doi.org/10.1523/JNEUROSCI.1920-10.2010
DeMarch Z, Giampà C, Patassini S et al (2007) Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol Dis 25:266–273. https://doi.org/10.1016/j.nbd.2006.09.006
Der HR, Wiemerslage L, LaBreck CJ et al (2014) The neuroprotective effect of human uncoupling protein 2 (hUCP2) requires cAMP-dependent protein kinase in a toxin model of Parkinson’s disease. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2014.05.032
Desdouits F, Cohen D, Nairn AC et al (1995a) Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase I in vitro and in vivo. J Biol Chem. https://doi.org/10.1074/jbc.270.15.8772
Desdouits F, Siciliano JC, Greengard P, Girault JA (1995b) Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc Natl Acad Sci USA 92:2682–2685. https://doi.org/10.1073/pnas.92.7.2682
Dietsch G, DiPalma C, Eyre R et al (2006) Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 34:39–51. https://doi.org/10.1080/01926230500385549
Dong W, li, Zhong J hong, Chen Y qing, et al (2021a) Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson’s disease models. Acta Pharmacol Sin. https://doi.org/10.1038/s41401-021-00768-4
Dong XL, Wang YH, Xu J, Zhang N (2021b) The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway. Sci Rep. https://doi.org/10.1038/s41598-021-98743-w
DrugBank (2005) https://go.drugbank.com/
Dumaz N, Marais R (2005) Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the gesellschaft fur biochemie und molekularbiologie lecture delivered on 5 July 2003 at the special FEBS meeting in brussels. FEBS J 272:3491–3504. https://doi.org/10.1111/j.1742-4658.2005.04763.x
Erro R, Mencacci NE, Bhatia KP (2021) The emerging role of phosphodiesterases in movement disorders. Mov Disord 36:2225–2243. https://doi.org/10.1002/mds.28686
Feng H, Wang C, He W et al (2019) Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects. Metab Brain Dis. https://doi.org/10.1007/s11011-018-0374-4
Finkbeiner S, Tavazoie SF, Maloratsky A et al (1997) CREB: A major mediator of neuronal neurotrophin responses. Neuron. https://doi.org/10.1016/S0896-6273(00)80395-5
Fornai F, Schlüter OM, Lenzi P et al (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.0409713102
Gavaldà A, Roberts RS (2013) Phosphodiesterase-4 inhibitors: a review of current developments (2010–2012). Expert Opin Ther Pat 23:997–1016. https://doi.org/10.1517/13543776.2013.794789
Ghosh A, Roy A, Liu X et al (2007) Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.0704908104
Ghosh M, Garcia-Castillo D, Aguirre V et al (2012) Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury. Glia. https://doi.org/10.1002/glia.22401
Girault JA, Hemmings HC, Williams KR et al (1989) Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J Biol Chem. https://doi.org/10.1016/s0021-9258(20)88248-9
Gong J, Zhang L, Zhang Q et al (2018) Lentiviral vector-mediated SHC3 silencing exacerbates oxidative stress injury in nigral dopamine neurons by regulating the PI3K-AKT-FoxO signaling pathway in rats with Parkinson’s disease. Cell Physiol Biochem. https://doi.org/10.1159/000493228
Grover M, Farrugia G, Stanghellini V (2019) Gastroparesis: a turning point in understanding and treatment. Gut 68:2238–2250. https://doi.org/10.1136/gutjnl-2019-318712
Gui C, Ren Y, Chen J et al (2020) p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant A53T α-synuclein model of Parkinson’s disease. Toxicol Appl Pharmacol. https://doi.org/10.1016/j.taap.2019.114874
Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol. https://doi.org/10.1007/978-3-642-17969-3_7
Hang L, Wang Z, Foo ASC et al (2021) Conditional disruption of AMP kinase in dopaminergic neurons promotes Parkinson’s disease-associated phenotypes in vivo. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2021.105560
Heckman PRA, van Duinen MA, Bollen EPP et al (2016) Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyw030
Heckman PRA, Blokland A, Van Goethem NP et al (2018) The mediating role of phosphodiesterase type 4 in the dopaminergic modulation of motor impulsivity. Behav Brain Res 350:16–22. https://doi.org/10.1016/j.bbr.2018.05.017
Hemmings HC, Greengard P, Tung HYL, Cohen P (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. https://doi.org/10.1038/310503a0
Hernandez-Baltazar D, Mendoza-Garrido ME, Martinez-Fong D (2013) Activation of GSK-3β and caspase-3 occurs in nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS ONE. https://doi.org/10.1371/journal.pone.0070951
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479. https://doi.org/10.1146/annurev.biochem.67.1.425
Hervé R, Schmitz T, Evain-Brion D et al (2008) The PDE4 inhibitor rolipram prevents NF-κB binding activity and proinflammatory cytokine release in human chorionic cells. J Immunol 181:2196–2202. https://doi.org/10.4049/jimmunol.181.3.2196
Hill EV, Sheppard CL, Cheung YF et al (2006) Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579. Cell Signal. https://doi.org/10.1016/j.cellsig.2006.07.018
Hoffmann R, Baillie GS, MacKenzie SJ et al (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at ser579. EMBO J. https://doi.org/10.1093/emboj/18.4.893
Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Progress in Nucleic Acid Research and Molecular Biology. Elsevier, Amsterdam, pp 249–315
Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1–18. https://doi.org/10.1042/bj20021698
Houslay MD, Schafer P, Zhang KYJ (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503–1519. https://doi.org/10.1016/S1359-6446(05)03622-6
Houslay MD, Baillie GS, Maurice DH (2007) cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system. Circ Res. https://doi.org/10.1161/01.res.0000261934.56938.38
Howells DW, Porritt MJ, Wong JYF et al (2000) Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol 166:127–135. https://doi.org/10.1006/exnr.2000.7483
Huai Q, Colicelli J, Ke H (2003a) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry. https://doi.org/10.1021/bi034653e
Huai Q, Wang H, Sun Y et al (2003b) Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure. https://doi.org/10.1016/S0969-2126(03)00123-0
Hulley P, Hartikka J, Abdel’Al S, et al (1995a) Inhibitors of Type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur J Neurosci 7:2431–2440. https://doi.org/10.1111/j.1460-9568.1995.tb01041.x
Hulley P, Hartikka J, Lubbert H (1995b) Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+. J Neural Transm Suppl 217–228
Hunot S, Brugg B, Ricard D et al (1997) Nuclear translocation of NF-κb is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.94.14.7531
Ivkovic S, Ehrlich ME (1999) Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci. https://doi.org/10.1523/jneurosci.19-13-05409.1999
Jabaris SSL, Sumathy H, Girish R et al (2015) Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system. Brain Res 1622:279–291. https://doi.org/10.1016/j.brainres.2015.07.003
Jeon YH, Heo Y-S, Kim CM et al (2005) Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62:1198–1220. https://doi.org/10.1007/s00018-005-4533-5
Ji HL, Richter W, Namkung W et al (2007) Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem 282:10414–10422. https://doi.org/10.1074/jbc.M610857200
Johnston LA, Erdogan S, Cheung YF et al (2004) Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochem J. https://doi.org/10.1042/BJ20031662
Jovanović-Mićić D, Štrbac M, Krstić SK et al (1989) Ablation of the area postrema and emesis. Metab Brain Dis 4:55–60. https://doi.org/10.1007/BF00999494
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Ke H (2004) Implications of PDE4 structure on inhibitor selectivity across PDE families. Int J Impot Res. https://doi.org/10.1038/sj.ijir.3901211
Keating GM (2017) Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. https://doi.org/10.1007/s40265-017-0709-1
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96
Khan AD, Singh L (2016) Various techniques of bioavailibility enhancement: a review. J Drug Deliv Ther. https://doi.org/10.22270/jddt.v6i3.1228
Khan AA, Mudassir J, Mohtar N, Darwis Y (2013) Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine 8:2733–2744
Kinoshita K, Muroi Y, Unno T, Ishii T (2017) Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of {Parkinson}’s disease. J Pharmacol Sci 134:55–58. https://doi.org/10.1016/j.jphs.2017.04.002
Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a008888
Kumar A, Singh N (2017) Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer’s Type. Biomed Pharmacother. https://doi.org/10.1016/j.biopha.2017.01.059
Kwak HJ, Park KM, Choi HE et al (2008) PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal. https://doi.org/10.1016/j.cellsig.2007.12.011
Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367–374. https://doi.org/10.1016/j.neuropharm.2010.05.004
Lamontagne S, Meadows E, Luk P et al (2001) Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 920:84–96. https://doi.org/10.1016/S0006-8993(01)03023-2
Larsen J, Lambert M, Pettersson H et al (2020) Discovery and early clinical development of isobutyl 1-[8-Methoxy-5-(1-oxo-3 H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel “dual-Soft” PDE4 inhibitor for topical treatment of atopic dermatitis. J Med Chem 63:14502–14521. https://doi.org/10.1021/acs.jmedchem.0c00797
Li M (2021) The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases. Apoptosis 26:235–247. https://doi.org/10.1007/s10495-021-01667-z
Li X, Zhang H, Niu Q, Yuan F (2012) Changes of cdk5, p35 and p53 gene expression levels in arsenic-induced neural cell apoptosis. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 30:85–88
Li H, Zuo J, Tang W (2018) Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. https://doi.org/10.3389/fphar.2018.01048
Liang J, Huang YY, Zhou Q et al (2020) Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia. J Med Chem 63:3370–3380. https://doi.org/10.1021/acs.jmedchem.0c00060
Lim K-L (2007) Ubiquitin–proteasome system dysfunction in Parkinson’s disease: current evidence and controversies. Expert Rev Proteomics 4:769–781. https://doi.org/10.1586/14789450.4.6.769
Liu J, Gao J, Tu S et al (2014) Neuroprotective effects of Jitai tablet, a traditional Chinese medicine, on the MPTP-induced acute model of Parkinson’s disease: involvement of the dopamine system. Evid-Based Complement Altern Med. https://doi.org/10.1155/2014/542383
Lokireddy S, Kukushkin NV, Goldberg AL (2015) cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.1522332112
Lourenco CM, Houle S, Wilson AA, DaSilva JN (2001) Characterization of R-[11C]rolipram for PET imaging of phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies in rats. Nucl Med Biol 28:347–358. https://doi.org/10.1016/S0969-8051(01)00206-2
Luo D, Zhao J, Cheng Y et al (2018) N-propargyl caffeamide (PACA) ameliorates dopaminergic neuronal loss and motor dysfunctions in MPTP mouse model of Parkinson’s disease and in MPP+-induced neurons via promoting the conversion of proNGF to NGF. Mol Neurobiol. https://doi.org/10.1007/s12035-017-0486-6
Luo S, Kang SS, Wang ZH et al (2019) Akt phosphorylates NQO1 and triggers its degradation, abolishing its antioxidative activities in Parkinson’s disease. J Neurosci. https://doi.org/10.1523/JNEUROSCI.0625-19.2019
MacKenzie SJ, Baillie GS, McPhee I et al (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br J Pharmacol. https://doi.org/10.1038/sj.bjp.0704743
Martinez A, Gil C (2013) CHAPTER 12. Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson’s Disease. pp 294–307
Mattson MP, Camandola S (2001) NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107:247–254. https://doi.org/10.1172/JCI11916
Maurice DH, Ke H, Ahmad F et al (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13:290–314. https://doi.org/10.1038/nrd4228
McDonough W, Aragon IV, Rich J et al (2020a) PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice. FASEB J 34:12533–12548. https://doi.org/10.1096/fj.202001016RR
McDonough W, Rich J, Aragon IV et al (2020b) Inhibition of type 4 cAMP-phosphodiesterases (PDE4s) in mice induces hypothermia via effects on behavioral and central autonomous thermoregulation. Biochem Pharmacol. https://doi.org/10.1016/j.bcp.2020.114158
Mcgirr A, Lipina TV, Mun HS et al (2016) Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition. Neuropsychopharmacology. https://doi.org/10.1038/npp.2015.240
Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670. https://doi.org/10.1038/nrd2058
Millar JK, Pickard BS, Mackie S et al (2005) Genetics: DISC1 and PDE4B are interacting genetic factors in schizoprenia that regulate cAMP signaling. Science. https://doi.org/10.1126/science.1112915
Miró X, Pérez-Torres S, Puigdomènech P et al (2002) Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 45:259–269. https://doi.org/10.1002/syn.10100
Mori F, Pérez-Torres S, De Caro R et al (2010) The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 40:36–42. https://doi.org/10.1016/j.jchemneu.2010.03.004
Moustafa AA, Chakravarthy S, Phillips JR et al (2016) Motor symptoms in Parkinson’s disease: a unified framework. Neurosci Biobehav Rev 68:727–740. https://doi.org/10.1016/j.neubiorev.2016.07.010
Mucignat C, Caretta A (2017) Drug-induced Parkinson’s disease modulates protein kinase A and olfactory marker protein in the mouse olfactory bulb. Behav Brain Funct. https://doi.org/10.1186/s12993-017-0119-2
Myeku N, Clelland CL, Emrani S et al (2016) Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. https://doi.org/10.1038/nm.4011
Naro F, Zhang R, Conti M (1996) Developmental regulation of unique adenosine 3′,5′-monophosphate-specific phosphodiesterase variants during rat spermatogenesis. Endocrinology 137:2464–2472. https://doi.org/10.1210/endo.137.6.8641200
Nelissen E, van Goethem NP, Bonassoli VT et al (2019) Validation of the xylazine/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats. Neurosci Lett 699:41–46. https://doi.org/10.1016/j.neulet.2019.01.026
Nestler EJ, Gould E, Manji H (2002) Preclinical models: status of basic research in depression. Biol Psychiatry 52:503–528
Nguyen HO, Schioppa T, Tiberio L et al (2022) The PDE4 inhibitor tanimilast blunts proinflammatory dendritic cell activation by SARS-CoV-2 ssRNAs. Front Immunol 12:1–12. https://doi.org/10.3389/fimmu.2021.797390
Niccolini F, Wilson H, Pagano G et al (2017) Loss of phosphodiesterase 4 in Parkinson disease. Neurology. https://doi.org/10.1212/WNL.0000000000004201
Nishi A, Shuto T (2017) Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders. Expert Opin Ther Targets 21:259–272. https://doi.org/10.1080/14728222.2017.1279149
Nishi A, Snyder GL (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Pharmacol Sci 114:6–16. https://doi.org/10.1254/jphs.10r01fm
Nishi A, Snyder GL, Greengard P (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17:8147–8155. https://doi.org/10.1523/jneurosci.17-21-08147.1997
Nishi A, Bibb JA, Snyder GL et al (2000) Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci U S A 97:12840–12845. https://doi.org/10.1073/pnas.220410397
Nthenge-Ngumbau DN, Mohanakumar KP (2018) Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson’s disease? Mol Neurobiol 55:822–834. https://doi.org/10.1007/s12035-016-0355-8
Oddo S (2008) The ubiquitin-proteasome system in Alzheimer’s disease. J Cell Mol Med. https://doi.org/10.1111/j.1582-4934.2008.00276.x
Omar B, Zmuda-Trzebiatowska E, Manganiello V et al (2009) Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A Epac and lipolysis. Cell Signal. https://doi.org/10.1016/j.cellsig.2009.01.015
Ouimet CC, Greengard P (1990) Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J Neurocytol. https://doi.org/10.1007/BF01188438
Paes D, Schepers M, Rombaut B et al (2021) The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitorss. Pharmacol Rev 73:1016–1049. https://doi.org/10.1124/pharmrev.120.000273
Page CP (2014) Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 165:152–164. https://doi.org/10.1159/000368800
Pagès L, Gavaldà A, Lehner MD (2009) PDE4 inhibitors: a review of current developments (2005–2009). Expert Opin Ther Pat 19:1501–1519. https://doi.org/10.1517/13543770903313753
Pallàs M, Pizarro JG, Gutierrez-Cuesta J et al (2008) Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience. https://doi.org/10.1016/j.neuroscience.2008.04.065
Park SJ, Ahmad F, Philp A et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. https://doi.org/10.1016/j.cell.2012.01.017
Parker CA, Matthews JC, Gunn RN et al (2005) Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4. Synapse 55:270–279. https://doi.org/10.1002/syn.20114
Paton DM (2017) Crisaborole: phosphodiesterase inhibitor for treatment of atopic dermatitis. Drugs of Today. https://doi.org/10.1358/dot.2017.53.4.2604174
Pauwelyn V, Ceelen W, Lefebvre RA (2018) Synergy between 5-HT4 receptor stimulation and phosphodiesterase 4 inhibition in facilitating acetylcholine release in human large intestinal circular muscle. Neurogastroenterol Motil. https://doi.org/10.1111/nmo.13162
Peng S, Zhang Y, Zhang J et al (2010) ERK in learning and memory: a review of recent research. Int J Mol Sci 11:222–232. https://doi.org/10.3390/ijms11010222
Pérez-Torres S, Miró X, Palacios JM et al (2000) Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat 20:349–374. https://doi.org/10.1016/S0891-0618(00)00097-1
Peter D, Göggel R, Colbatzky F, Nickolaus P (2011) Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats. Br J Pharmacol 162:415–427. https://doi.org/10.1111/j.1476-5381.2010.01035.x
Poewe W (2008) Non-motor symptoms in Parkinson’s disease. Eur J Neurol 15:14–20. https://doi.org/10.1111/j.1468-1331.2008.02056.x
Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Prim. https://doi.org/10.1038/nrdp.2017.13
Prickaerts J, Heckman PRA, Blokland A (2017) Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert Opin Investig Drugs 26:1033–1048. https://doi.org/10.1080/13543784.2017.1364360
Puurunen J, Lücke C, Schwabe U (1978) Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol 304:69–75. https://doi.org/10.1007/BF00501379
Qiu W, Zhuang S, Von Lintig FC et al (2000) Cell type-specific regulation of B-Raf kinase by cAMP and 14–3-3 proteins. J Biol Chem. https://doi.org/10.1074/jbc.M003327200
Rau TF, Kothiwal A, Zhang L et al (2011) Low dose methamphetamine mediates neuroprotection through a PI3K-AKT pathway. Neuropharmacology 61:677–686. https://doi.org/10.1016/j.neuropharm.2011.05.010
Rehman NU, Ansari MN, Samad A (2020) In silico, ex vivo and in vivo studies of roflumilast as a potential antidiarrheal and antispasmodic agent: inhibition of the PDE-4 enzyme and voltage-gated Ca++ ion channels. Molecules. https://doi.org/10.3390/molecules25041008
Reyes-Irisarri E, Sánchez AJ, García-Merino JA, Mengod G (2007) Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol. https://doi.org/10.1097/nen.0b013e3181567c31
Rhee CK, Kim DK (2020) Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease. Korean J Intern Med 35:276–283. https://doi.org/10.3904/kjim.2020.035
Richter W, Conti M (2002) Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J Biol Chem. https://doi.org/10.1074/jbc.M203585200
Richter W, Conti M (2004) The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem. https://doi.org/10.1074/jbc.M312687200
Robichaud A, Savoie C, Stamatiou PB et al (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40:262–269. https://doi.org/10.1016/S0028-3908(00)00142-8
Robichaud A, Stamatiou PB, Jin S-LC et al (2002) Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. https://doi.org/10.1172/jci200215506
Roflumilast U.S. approval D (2011) DALIRESP® (roflumilast) tablets Initial U.S. Approval: 2011,. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022522s009lbl.pdf
Roos-Mattjus P, Sistonen L (2004) The ubiquitin-proteasome pathway. Ann Med 36:285–295. https://doi.org/10.1080/07853890310016324
Russo I (2019) The role of LRRK2 on PKA-NFκB pathway in microglia cells: implications for Parkinson’s disease. Neural Regen Res 14:1713. https://doi.org/10.4103/1673-5374.257523
Russo I, Bubacco L, Greggio E (2014) LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease? J Neuroinflammation 11:52. https://doi.org/10.1186/1742-2094-11-52
Russo I, Di Benedetto G, Kaganovich A et al (2018) Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. J Neuroinflammation 15:297. https://doi.org/10.1186/s12974-018-1337-8
Sandebring A, Thomas KJ, Beilina A et al (2009) Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS ONE. https://doi.org/10.1371/journal.pone.0005701
Saroj P, Bansal Y, Singh R et al (2021) Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington’s disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway. Inflammopharmacology. https://doi.org/10.1007/s10787-020-00787-3
Schafer PH, Parton A, Gandhi AK et al (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. https://doi.org/10.1111/j.1476-5381.2009.00559.x
Schwartz AL, Ciechanover A (1999) The ubiquitin-proteasome pathway and pathogenesis of human diseases. Ann Rev Med 50(1):57–74. https://doi.org/10.1146/annurev.med.50.1.57
Schwenkgrub J, Zaremba M, Joniec-Maciejak I et al (2017) The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0182019
Sevlever D, Jiang P, Yen SHC (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of α-synuclein and generation of its carboxy-terminally truncated species. Biochemistry. https://doi.org/10.1021/bi800699v
Shepherd M, McSorley T, Olsen AE et al (2003) Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem J 370:429–438. https://doi.org/10.1042/BJ20021082
Shirakawa F, Chedid M, Suttles J et al (1989) Interleukin 1 and cyclic AMP induce kappa immunoglobulin light-chain expression via activation of an NF-kappa B-like DNA-binding protein. Mol Cell Biol. https://doi.org/10.1128/mcb.9.3.959-964.1989
Sims CR, Singh SP, Mu S et al (2017) Rolipram improves outcome in a rat model of infant sepsis-induced cardiorenal syndrome. Front Pharmacol. https://doi.org/10.3389/fphar.2017.00237
Singh P, Hanson PS, Morris CM (2017) SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease. BMC Neurosci. https://doi.org/10.1186/s12868-017-0364-1
Sola P, Krishnamurthy P, Chintamaneni PK et al (2020) Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management. Expert Opin Drug Deliv 17:1119–1132. https://doi.org/10.1080/17425247.2020.1779218
Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308–315. https://doi.org/10.1038/bjp.2008.307
Srivastava P, Dhuriya YK, Gupta R et al (2018) Protective effect of curcumin by modulating BDNF/DARPP32/CREB in arsenic-induced alterations in dopaminergic signaling in rat corpus striatum. Mol Neurobiol. https://doi.org/10.1007/s12035-016-0288-2
Stipanovich A, Valjent E, Matamales M et al (2008) A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature 453:879–884. https://doi.org/10.1038/nature06994
Sullivan M, Olsen AS, Houslay MD (1999) Genomic organisation of the human cyclic AMP-specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between RAB3A and JUND. Cell Signal. https://doi.org/10.1016/S0898-6568(99)00037-6
Sun S-C, Chang J-H, Jin J (2013) Regulation of nuclear factor-κB in autoimmunity. Trends Immunol 34:282–289. https://doi.org/10.1016/j.it.2013.01.004
Suzuki O, Mizukami K, Etori M et al (2013) Evaluation of the therapeutic index of a novel phosphodiesterase 4B - selective inhibitor over phosphodiesterase 4D in mice. J Pharmacol Sci 123:219–226. https://doi.org/10.1254/jphs.13103FP
Svenningsson P, Tzavara ET, Carruthers R et al (2003) Diverse psychotomimetics act through a common signaling pathway. Science. https://doi.org/10.1126/science.1089681
Swinnen JV, Joseph DR, Conti M (1989) Molecular cloning of rat homologues of the drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.86.14.5325
Takahashi M, Terwilliger R, Lane C et al (1999) Chronic antidepressant administration increases the expression of cAMP- specific phosphodiesterase 4A and 4B isoforms. J Neurosci 19:610–618. https://doi.org/10.1523/jneurosci.19-02-00610.1999
Takano A, Uz T, Garcia-Segovia J et al (2018) A Nonhuman primate PET study: measurement of brain PDE4 occupancy by roflumilast using (R)-[11C]Rolipram. Mol Imaging Biol 20:615–622. https://doi.org/10.1007/s11307-018-1168-0
Takuma K, Lee E, Enomoto R et al (2001) Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br J Pharmacol. https://doi.org/10.1038/sj.bjp.0704146
Tang TS, Bezprozvaany I (2004) Dopamine receptor-mediated Ca2+ signaling in striatal medium spiny neurons. J Biol Chem. https://doi.org/10.1074/jbc.M407389200
Tang L, Huang C, Zhong J et al (2019) Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect. Eur J Med Chem 168:221–231. https://doi.org/10.1016/j.ejmech.2019.02.026
Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510–518. https://doi.org/10.1016/j.nbd.2009.11.004
Tashkin DP (2014) Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother 15:85–96. https://doi.org/10.1517/14656566.2013.837159
Taylor AE, Saint-cyr JA, Lang AE (1986) Frontal lobe dysfunction in parkinson’s disease: the cortical focus of neostriatal outflow. Brain 109:845–883. https://doi.org/10.1093/brain/109.5.845
Tetra Discovery Partners (2016) Tetra Discovery Partners Announces Positive Results from Phase 1 Studies of Cognition Drug Candidate, BPN14770. 0–2. https://tetratherapeutics.com/wp-content/uploads/2016/11/FINAL-Tetra-Phase-1-121616-FINAL.pdf
Tibbo AJ, Tejeda GS, Baillie GS (2019) Understanding PDE4’s function in Alzheimer’s disease A target for novel therapeutic approaches. Biochem Soc Trans. https://doi.org/10.1042/BST20190763
Titus D, Oliva A, Wilson N, Atkins C (2014) Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. Curr Pharm Des. https://doi.org/10.2174/1381612820666140826113731
Titus DJ, Wilson NM, Alcazar O et al (2018) A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury. Neurobiol Learn Mem 148:38–49. https://doi.org/10.1016/j.nlm.2017.12.008
Tofaris GK, Razzaq A, Ghetti B et al (2003) Ubiquitination of α-synuclein in lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. https://doi.org/10.1074/jbc.M308041200
Tong H, Zhang X, Meng X et al (2018) Simvastatin inhibits activation of nadph oxidase/p38 MAPK pathway and enhances expression of antioxidant protein in parkinson disease models. Front Mol Neurosci. https://doi.org/10.3389/fnmol.2018.00165
Torphy TJ, Barnette MS, Underwood DC et al (1999) ArifloTM(SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 12:131–135. https://doi.org/10.1006/pupt.1999.0181
Troncoso-Escudero P, Parra A, Nassif M, Vidal RL (2018) Outside in: unraveling the role of neuroinflammation in the progression of Parkinson’s disease. Front Neurol. https://doi.org/10.3389/fneur.2018.00860
Tysnes O-B, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm 124:901–905. https://doi.org/10.1007/s00702-017-1686-y
Vallee BL, Auld DS (1990) Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry. https://doi.org/10.1021/bi00476a001
VerPlank JJS, Goldberg AL (2017) Regulating protein breakdown through proteasome phosphorylation. Biochem J 474:3355–3371. https://doi.org/10.1042/BCJ20160809
Vogt Weisenhorn DM, Roback LJ, Kwon JH, Wainer BH (2001) Coupling of cAMP/PKA and MAPK signaling in neuronal cells is dependent on developmental stage. Exp Neurol. https://doi.org/10.1006/exnr.2001.7651
Wachtel H (1982) Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77:309–316. https://doi.org/10.1007/BF00432761
Wachtel H (1983) Neurotropic effects of the optical isomers of the selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J Pharm Pharmacol 35:440–444. https://doi.org/10.1111/j.2042-7158.1983.tb04318.x
Wang P, Wu P, Ohleth KM et al (1999) Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. https://doi.org/10.1124/mol.56.1.170
Wang C, Ko HS, Thomas B et al (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum Mol Genet 14:3885–3897. https://doi.org/10.1093/hmg/ddi413
Wang XF, Li S, Chou AP, Bronstein JM (2006) Inhibitory effects of pesticides on proteasome activity: implication in Parkinson’s disease. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2006.02.012
Wang H, Peng MS, Chen Y et al (2007) Structures of the four subfamilies of phosphodiesterases provide insight into the selectivity of their inhibitors. Biochem J. https://doi.org/10.1042/BJ20070970
Wang G, Chen L, Pan X et al (2016) The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Oncotarget 7:17380–17392. https://doi.org/10.18632/oncotarget.8041
Wang H, Xu J, Lazarovici P et al (2018) cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia. Front Mol Neurosci. https://doi.org/10.3389/fnmol.2018.00255
Wang Z, Dong H, Wang J et al (2020) Pro-survival and anti-inflammatory roles of NF-κB c-Rel in the Parkinson’s disease models. Redox Biol. https://doi.org/10.1016/j.redox.2020.101427
Watson GS, Leverenz JB (2010) Profile of cognitive impairment in Parkinson’s disease. Brain Pathol 20:640–645. https://doi.org/10.1111/j.1750-3639.2010.00373.x
Wilcox DE (1996) Binuclear metallohydrolases. Chem Rev. https://doi.org/10.1021/cr950043b
Wilson H, Pagano G, Niccolini F et al (2020) The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson’s disease. Park Relat Disord. https://doi.org/10.1016/j.parkreldis.2019.02.027
Wu Y, Li X, Zhu JX et al (2011) Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease. Neurosignals. https://doi.org/10.1159/000328516
Xia C, He JP, Feng KW et al (2022) Discovery of novel 3-Amino-4-alkoxyphenylketones as PDE4 inhibitors with improved oral bioavailability and safety against spatial memory impairments. ACS Chem Neurosci 13:390–405
Xu RX, Hassell AM, Vanderwall D et al (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. https://doi.org/10.1126/science.288.5472.1822
Xu B, Wang T, Xiao J et al (2019) FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3β/ β-catenin signaling pathway. Biochem Pharmacol. https://doi.org/10.1016/j.bcp.2019.02.023
Yamada K, Takahashi S, Karube F et al (2016) Neuronal circuits and physiological roles of the basal ganglia in terms of transmitters, receptors and related disorders. J Physiol Sci 66:435–446. https://doi.org/10.1007/s12576-016-0445-4
Yan T, Sun Y, Gong G et al (2019) The neuroprotective effect of schisandrol A on 6-OHDA-induced PD mice may be related to PI3K/AKT and IKK/IκBα/NF-κB pathway. Exp Gerontol. https://doi.org/10.1016/j.exger.2019.110743
Yang L, Calingasan NY, Lorenzo BJ, Beal MF (2008) Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol. https://doi.org/10.1016/j.expneurol.2007.02.010
Yang L, Wang H, Liu L, Xie A (2018) The role of insulin/IGF-1/PI3K/Akt/GSK3β signaling in Parkinson’s disease dementia. Front Neurosci. https://doi.org/10.3389/fnins.2018.00073
Yger M, Girault JA (2011) DARPP-32, jack of all trades...master of which? Front Behav Neurosci, Doi: https://doi.org/10.3389/fnbeh.2011.00056
Yin W, Mu J, Birnbaum MJ (2003) Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 adipocytes. J Biol Chem. https://doi.org/10.1074/jbc.M308484200
Young M, Roebuck HL (2016) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. https://doi.org/10.1002/2327-6924.12428
Yu S, Pearson AD, Lim RKV et al (2016) Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody-drug conjugate. Mol Ther 24:2078–2089. https://doi.org/10.1038/mt.2016.175
Yuan H, Zhang Z-W, Liang L-W et al (2010) Treatment strategies for Parkinson’s disease. Neurosci Bull 26:66–76. https://doi.org/10.1007/s12264-010-0302-z
Yuan NN, Cai CZ, JmY Wu et al (2019) Canthin-6-one accelerates alpha-synuclein degradation by enhancing UPS activity: drug target identification by CRISPR-Cas9 whole genome-wide screening technology. Front Pharmacol. https://doi.org/10.3389/fphar.2019.00016
Zhang H-T (2009) Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des. https://doi.org/10.2174/138161209788168092
Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12:9–18. https://doi.org/10.1038/sj.cr.7290105
Zhong Y, Chen AF, Zhao J et al (2016) Serum levels of cathepsin D, sirtuin1, and endothelial nitric oxide synthase are correlatively reduced in elderly healthy people. Aging Clin Exp Res. https://doi.org/10.1007/s40520-015-0472-7
Zhong J, Yu H, Huang C et al (2018) Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress. Redox Biol. https://doi.org/10.1016/j.redox.2018.02.008
Zhong J, Xie J, Xiao J et al (2019) Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP + -induced oxidative insult. Free Radic Biol Med. https://doi.org/10.1016/j.freeradbiomed.2019.02.027
Zhong J, Dong W, Qin Y et al (2020) Roflupram exerts neuroprotection via activation of CREB/PGC-1α signalling in experimental models of Parkinson’s disease. Br J Pharmacol. https://doi.org/10.1111/bph.14983
Zhong J, Li M, Xu J et al (2022) Roflupram attenuates α-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant α-synuclein. Toxicol Appl Pharmacol. https://doi.org/10.1016/j.taap.2021.115859
Zhou Y, Wu Z, Cao X et al (2016a) HNO suppresses LPS-induced inflammation in BV-2 microglial cells via inhibition of NF-κB and p38 MAPK pathways. Pharmacol Res. https://doi.org/10.1016/j.phrs.2016.08.007
Zhou ZZ, Ge BC, Zhong QP et al (2016b) Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. Eur J Med Chem 124:372–379. https://doi.org/10.1016/j.ejmech.2016.08.052
Zhu JH, Guo F, Shelburne J et al (2003) Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in lewy body diseases. Brain Pathol. https://doi.org/10.1111/j.1750-3639.2003.tb00478.x
Zou ZQ, Chen JJ, Feng HF et al (2017) Novel phosphodiesterase 4 inhibitor FCPR03 alleviates lipopolysaccharide-induced neuroinflammation by regulation of the cAMP/PKA/CREB signaling pathway and NF-κB inhibition. J Pharmacol Exp Ther. https://doi.org/10.1124/jpet.116.239608
Acknowledgements
The authors acknowledge and thank the Department of Science and Technology – Fund for Improvement of Science and Technology Infrastructure in Universities and Higher Educational Institutions (DST-FIST), Govt. of India, New Delhi, for their infrastructure and support to our department (Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India).
Funding
None.
Author information
Authors and Affiliations
Contributions
Conceptualization, DR, SB; Investigation, DR, SB, PS; Writing – Original Draft, DR, PS; Writing – Review & Editing, DR, SB, PTK, PS, ER; Visualization, DR, SB, PS, ER; Supervision, SB. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
Not applicable.
Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Roy, D., Balasubramanian, S., Krishnamurthy, P.T. et al. Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential. Cell Mol Neurobiol 43, 2713–2741 (2023). https://doi.org/10.1007/s10571-023-01349-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-023-01349-1